Verastem, Inc. Stock Plummets to New 52-Week Low of $4.00

Verastem, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 4.00 on May 21, 2026. This marks a significant decline for the company, which has seen its stock price fluctuate considerably over the past year. Despite a 1-year performance of 28.61%, Verastem has struggled to keep pace with the S&P 500, which recorded a return of 27.39% during the same period. The company's market capitalization stands at USD 510 million, and it currently operates at a loss, reflected in its negative price-to-earnings ratio. Financial metrics indicate challenges, with net sales declining at an annual rate of -9.16% over the last five years. The company reported a net profit of USD -83.15 million, a decrease of 48.81%, and an operating cash flow of USD -132.66 million, the lowest recorded. Additionally, Verastem's return on equity is notably high at 1,021.15%, but this figure is overshadowed by its debt-to-equity ratio of 3.11, indicating a potentially risky financial position. As Verastem navigates these challenges, the recent drop to a 52-week low highlights the ongoing volatility in its stock performance.